- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
CC-93269 is an investigational, humanized IgG1-based 2+1 T-cell engager (TCE) designed to bind to B-cell maturation antigen (BCMA) on malignant and non-malignant plasma cells and CD3? on T cells, thus coupling both cell types.1,2 This simultaneous binding is proposed to result in T-cell activation and cytokine release, followed by cytolytic synapse formation and secretion of cytolytic enzymes.1,2